[Drug resistance in lung cancer].
Szturmowicz
M
M
Kliniki Chorób Wewnetrznych Klatki Piersiowej Instytutu Gruźlicy i Chorób Płuc w Warszawie.
D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology; D004264:DNA Topoisomerases, Type I / Q000187:drug effects / Q000378:metabolism; D018432:Drug Resistance, Multiple / Q000502:physiology; D019008:Drug Resistance, Neoplasm; D004789:Enzyme Activation / Q000187:drug effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D008297:Male; D013379:Substrate Specificity; D014404:Tubulin / Q000187:drug effects
D000970:Antineoplastic Agents; D014404:Tubulin; D004264:DNA Topoisomerases, Type I; D002945:Cisplatin